Loading quotes...

Forecast

Buy	0
Hold	1
Sell	2

News Go to news feed

Mallinckrodt: Acthar Gel shows improved results in study for ankylosing spondylitis and psoriatic arthritis

A cross-sectional study using physician surveys and chart review reported improvements after treatment with Acthar Gel in 95% of 63 ankylosing spondylitis (AS) patients and 88% of 77 psoriatic arthritis (PsA) patients. Among those who improved, 70% of AS and 63% of PsA patients reported relief of overall symptoms, and 68% and 62% reported reduced pain, respectively; about 30% were able to reduce their corticosteroid use. The study noted improvements in physical function, strength and fatigue but cited the lack of a control group and differences in documentation as limitations. Valuation models indicate that Mallinckrodt's stock is trading below its fair value. » More on de.investing.com
Mallinckrodt appoints Christiana Stamoulis as new CFO following merger with Endo

Mallinckrodt has appointed Christiana Stamoulis, previously CFO at Incyte, as its new Chief Financial Officer and President, effective September 22, 2025. The appointment comes shortly after the completion of the merger with Endo and is part of the company's strategic realignment following recent share price declines. Stamoulis brings extensive industry experience and will be responsible for leading the finance organization and corporate development. » More on de.investing.com
Mallinckrodt benefits from Endo acquisition and improved S&P rating

Following Mallinckrodt's acquisition of Endo, S&P Global has raised Endo's rating to 'BB-' and set the outlook to 'stable'. The planned spin-off of the generics business is seen by S&P as slightly credit negative, but this is partially offset by stronger growth and higher margins in the remaining branded business. S&P views Mallinckrodt's long-term viability as dependent on further acquisitions, but expects moderate revenue growth and stable debt metrics in the short term. » More on de.investing.com

Financials

In the last quarter, Mallinckrodt had revenue of €453.18M and net profit of €99.45M

(EUR)	June 2026	YoY
Revenue	453.18M	9.48%
Gross profit	247.09M	24.92%
Net profit	99.45M	4,756.11%
EBITDA	52.4M	9.57%

Fundamentals

Metric	Value
Market capitalization	€0
52-week high/low	€0.018 - €0.018
Dividends	No
Beta	2.72
P/E ratio	-0.01
PEG ratio	0.00
P/B ratio	0.01
P/S ratio	0.00

Company profile

Mallinckrodt plc develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands and Specialty Generics. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes; and gastrointestinal products. It offers Acthar Gel, a repository corticotropin injection for rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, severe acute and chronic allergic, and inflammatory diseases; INOmax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Therakos photopheresis, an immunotherapy treatment platform; Amitiza for constipation; and StrataGraft for the treatment of adults with deep partial-thickness burns. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; and SLN 501 is a ribonucleic acid silencing therap. In addition, it provides specialty generic drugs and active pharmaceutical ingredients. The company markets its branded products to physicians, respiratory therapists, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with Silence Therapeutics plc to develop and commercialize ribonucleic acid interference drug targets. The company was founded in 1867 and is based in Dublin, Ireland. On October 12, 2020, Mallinckrodt plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.